Y-mAbs Therapeutics' Q2 revenue falls 14%

Reuters

2025/08/08

Y-mAbs <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' <a href="https://laohu8.com/S/QTWO">Q2</a> revenue falls 14%

Overview

Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations
SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025
Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19

Outlook

Y-mAbs did not provide further guidance due to pending acquisition
Company to be acquired by SERB Pharmaceuticals by Q4 2025

Result Drivers

U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition
EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia
LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Product Revenue		$19.50 mln
Q2 EPS	Beat	-$0.07	-$0.27 (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52

Press Release: ID:nGNX47pmBL

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557523994"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557523994\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557523994?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557523994","market":"us","top_or_hot":-1,"title":"Y-mAbs Therapeutics' Q2 revenue falls 14%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls 14%</title></head><body><p><span>Overview</span></p><ul><li><p>Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations</p></li><li><p>SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025</p></li><li><p>Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19</p></li></ul><p><span>Outlook</span></p><ul><li><p>Y-mAbs did not provide further guidance due to pending acquisition</p></li><li><p>Company to be acquired by SERB Pharmaceuticals by Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition</p></li><li><p>EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia</p></li><li><p>LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Product Revenue</p></td><td></td><td><p>$19.50 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Beat</p></td><td><p>-$0.07</p></td><td><p>-$0.27 (9 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52</p></li></ul><p>Press Release: <span>ID:nGNX47pmBL</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Y-mAbs Therapeutics' Q2 revenue falls 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nY-mAbs Therapeutics' Q2 revenue falls 14%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-08 18:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls 14%</title></head><body><p><span>Overview</span></p><ul><li><p>Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations</p></li><li><p>SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025</p></li><li><p>Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19</p></li></ul><p><span>Outlook</span></p><ul><li><p>Y-mAbs did not provide further guidance due to pending acquisition</p></li><li><p>Company to be acquired by SERB Pharmaceuticals by Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition</p></li><li><p>EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia</p></li><li><p>LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Product Revenue</p></td><td></td><td><p>$19.50 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Beat</p></td><td><p>-$0.07</p></td><td><p>-$0.27 (9 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52</p></li></ul><p>Press Release: <span>ID:nGNX47pmBL</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YMAB","symbol_name":"Y-mAbs Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nPLX540158:1","article_id":"2557523994","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557523994","pubTimestamp":1754649883,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Y-mAbs Therapeutics' Q2 revenue falls 14%OverviewY-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectationsSERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025Co's acqui","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"YMAB":"Y-mAbs Therapeutics, Inc."},"translate_title":"Y-mAbs Therapeutics第二季度收入下降14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":0.9},"content_text":"Y-mAbs Therapeutics' Q2 revenue falls 14%OverviewY-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectationsSERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19OutlookY-mAbs did not provide further guidance due to pending acquisitionCompany to be acquired by SERB Pharmaceuticals by Q4 2025Result DriversU.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competitionEX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern AsiaLICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in IsraelKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Product Revenue$19.50 mlnQ2 EPSBeat-$0.07-$0.27 (9 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52Press Release: ID:nGNX47pmBL(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}